drugset
drugset / Trial / NCT06751121

Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori

NCT06751121 ↗

Phase 3 Completed 461 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for Helicobacter pylori

Timeline

Start
2024-02-06
Primary completion
2025-04-24
Completion
2025-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule 40 mg Oral
Comparator DWC202301 Unknown 30 mg Oral
Background Amoxicillin Other / unclassified 1000 mg Oral
Background Clarithromycin Small molecule 500 mg Oral

Indications

Helicobacter pylori infectious disease